Can Dr. Reddy’s build a biosimilars portfolio that rivals Biocon and global MNCs in regulated markets?

Dr. Reddy’s Laboratories Ltd (NSE: DRREDDY, NYSE: RDY) is accelerating its transition from a traditional generics leader into a global biosimilars challenger, with ambitions to rival incumbents such as Biocon Biologics, Amgen, and Sandoz. With late-stage biologics like rituximab and bevacizumab under regulatory review in the U.S. and Europe, and differentiated assets such as daratumumab and denosumab in the pipeline, the Hyderabad-based pharmaceutical innovator is actively reshaping its global identity. This strategic shift is being closely watched by institutional investors seeking exposure to high-value, margin-accretive biologics in regulated markets.

While the company’s strength in backward-integrated generics is well established, its biosimilars program could redefine its long-term value proposition—if its filings translate into approvals and meaningful market penetration.

How far has Dr. Reddy’s rituximab biosimilar progressed through US and EU regulatory review and what remains ahead?

The Hyderabad-based biosimilars developer reached a key inflection point in July 2023 when the U.S. Food and Drug Administration (FDA) accepted the Biologics License Application (BLA) for its rituximab biosimilar, DRL_RI. In Europe, the biosimilar—branded as Ituxredi—received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in July 2024. That recommendation paved the way for European Commission approval and potential rollout across EU member states.

However, progress in the U.S. was delayed when the FDA issued a Complete Response Letter (CRL) in April 2024. The agency flagged issues related to process validation and data traceability but did not raise safety, efficacy, or patent-related objections. Dr. Reddy’s Laboratories Ltd is currently addressing these concerns and is expected to resubmit in late 2025. If approved, Ituxredi would enter a rituximab market currently served by multiple biosimilar competitors, making pricing, access, and speed to market critical.

What clinical-stage biosimilars does Dr. Reddy’s have in its pipeline and what regulatory hurdles do they still face?

Dr. Reddy’s biosimilars pipeline has gained significant depth in the last two years, positioning it to expand its footprint in both oncology and autoimmune disease portfolios. Its bevacizumab biosimilar, branded as Versavo, was launched in the United Kingdom in March 2024 and is currently under review with the European Medicines Agency (EMA) for broader market authorization.

The oncology-focused drugmaker is also co-developing a daratumumab biosimilar (HLX15) through a strategic alliance with Shanghai Henlius Biotech, targeting multiple myeloma—a high-value indication with limited biosimilar competition. U.S. and EU filings are anticipated in 2025–2026. Another asset under co-development is denosumab (Prolia/Xgeva biosimilar), in partnership with Iceland-based Alvotech. Both companies submitted a BLA to the FDA in 2024, and Dr. Reddy’s holds exclusive commercialization rights in the U.S. and semi-exclusive rights in Europe.

Further back in the pipeline are early-stage biosimilars for trastuzumab and golimumab, which if successful, could extend Dr. Reddy’s reach into breast cancer and inflammatory arthritis markets respectively.

How does Dr. Reddy’s biosimilars portfolio compare to Biocon Biologics and global MNCs in terms of approvals and commercial scale?

Biocon Biologics remains the clear frontrunner among Indian biosimilars developers, with U.S. FDA and EMA-approved products such as Ogivri (trastuzumab), Fulphila (pegfilgrastim), and Semglee (insulin glargine) already commercialized in regulated markets. Its joint venture with Viatris allowed Biocon to achieve first-wave market access, especially in the U.S.

In contrast, Dr. Reddy’s is executing a second-wave biosimilars strategy focused on underpenetrated or newly emerging biologic targets. While it lacks the commercial traction of Biocon as of mid-2025, it is developing candidates in areas with high differentiation, lower biosimilar saturation, and stronger pricing power. By targeting assets like daratumumab and denosumab—which are newer to biosimilar competition—Dr. Reddy’s is attempting to leapfrog into a higher-margin, innovation-adjacent segment of the biosimilars market.

What are the critical regulatory, manufacturing, and market-access risks that could derail Dr. Reddy’s biosimilars launch plans?

Institutional investors continue to view regulatory clearance as the single biggest execution risk for Dr. Reddy’s Laboratories Ltd in its biosimilars roadmap. While its facilities are U.S. FDA and EU GMP compliant, the April 2024 CRL for rituximab underscored the importance of consistently maintaining inspection readiness, especially around process validation and data integrity systems.

Pricing pressure in biosimilars remains another major risk. Larger incumbents like Amgen and Sandoz have demonstrated a willingness to defend market share through aggressive discounting and bundled contracting with health systems. Dr. Reddy’s may face initial challenges in securing formulary placements in the U.S. and reimbursed access in select European countries, where biosimilar switching protocols are still evolving.

Lastly, co-development agreements, while efficient, reduce commercial control and can complicate global rollout timelines if partners face parallel regulatory issues.

What competitive advantages and commercialization strategies could help Dr. Reddy’s biosimilars succeed against more established rivals?

Despite risks, Dr. Reddy’s brings several advantages to its biosimilars strategy. The Indian pharmaceutical exporter has long operated with a vertically integrated model—from API synthesis to finished formulation—enabling cost leadership across therapeutic categories. This structure is being adapted to biologics with investments in EU-compliant monoclonal antibody facilities and dedicated biologics fill-finish lines.

Dr. Reddy’s also benefits from a global marketing network built through its generics business. It already serves over 60 countries and has relationships with key hospital chains, group purchasing organizations, and health ministries. This footprint gives it a foundation to negotiate biosimilar tenders, especially in emerging markets that may fast-track regulatory pathways.

Moreover, its product branding strategy (e.g., Ituxredi for rituximab, Versavo for bevacizumab) allows the Hyderabad-based biologics developer to build recall and loyalty, particularly in physician-driven markets like Latin America, Eastern Europe, and Southeast Asia.

What is the investor and institutional sentiment toward Dr. Reddy’s pivot into oncology and autoimmune biosimilars in regulated markets?

Investor sentiment toward Dr. Reddy’s Laboratories Ltd has been moderately bullish following its Q4 FY25 results, which highlighted increasing R&D spend—₹2,738 crore for the year, or 8.4% of revenues—and the pending resolution of FDA issues around rituximab. Analysts covering the Indian pharmaceutical sector have generally described the biosimilars strategy as well-positioned but contingent on smooth regulatory execution.

Institutional investors are taking a wait-and-see approach on commercial traction but acknowledge the pipeline’s depth and therapeutic focus as key positives. Unlike some peers that over-index on insulin or anti-TNF products, Dr. Reddy’s has diversified its assets across oncology, autoimmune diseases, and bone health—areas with longer life cycles and more defensible pricing structures.

What would successful biosimilars launches look like for Dr. Reddy’s by mid‑2026 and how would that shift its market positioning?

If the FDA clears DRL_RI in the next review cycle and Versavo expands to additional European markets, Dr. Reddy’s could generate its first meaningful biosimilars revenue in FY26. Successful launches of HLX15 (daratumumab) and the denosumab biosimilar could position it among the top five biosimilar developers globally within the next 24–36 months. Institutional investors suggest that capturing even a 10–12% market share in each approved biosimilar category could materially enhance EBITDA margins and ROCE from FY27 onwards.

This would also recalibrate the company’s public market narrative—from a value-oriented generics manufacturer to a mid-cap biologics innovator. For investors tracking Dr. Reddy’s Laboratories Ltd stock outlook in 2025, the coming year could be decisive in shaping its biosimilars credentials and long-term equity rerating potential.